T2DM Intensity Lifestyle Intervention

The Effect of mHealth-Based Lifestyle Intervention on Overweight or Obese Patients With Type 2 Diabetes: A Randomized Controlled Trial

This RCT study will evaluate the effect of a lifestyle intervention on overweight or obese patients with type 2 diabetes mellitus. The primary hypothesis is that the mHealth-based intensive lifestyle intervention is sufficient to achieve weight loss and maintain glycated hemoglobin control.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2; Overweight or Obesity
• Intervention / Treatment: Behavioral: lifestyle intervention

Detailed Description

Diabetes mellitus is a chronic systemic metabolic disease caused by the long-term interaction of genetic factors and environmental factors. It is characterized by an increase in plasma glucose levels and is mainly due to metabolic disorders in glucose, fat, and protein caused by insufficient insulin secretion and/or dysfunction in the body, which affects normal physiological activities. As of 2019, 463 million people are suffering from diabetes in the world, of which 90% to 95% have type 2 diabetes mellitus (T2DM), with an average of 1 patient in every 11 adults (aged 20-79). The number of patients with T2DM will jump to 700 million by 2045. There is a close relationship between T2DM and overweight and obesity. The prevalence of diabetes in overweight and obese people in China was 12.8% and 18.5%, respectively. Among T2DM patients, the proportions of overweight and obesity were 41% and 24.3%, respectively.The two kinds of diseases share a common key pathophysiological mechanism, which will have a devastating long-term impact on patients' health and bring serious disease and economic burden to the family. Given the various harms, it is urgent to carry out relevant intervention research and formulate effective intervention strategies. With the development of artificial intelligence technology, the combination of mHealth and multidisciplinary lifestyle intervention may become an efficient and easy-to-popularize management mode for the prevention and treatment of T2DM with obesity.

Given the relative lack of high-quality interventions for T2DM overweight/obesity, the investigators designed a randomized controlled trial to assess the effectiveness of a multicomponent intervention in Ningbo First Hospital. This study plans to adopt the online and offline combination method based on mHealth technology to carry out lifestyle intervention aimed at formulating a set of feasible and effective intervention strategies.

The study aims to identify: 1) whether the mHealth-based intensive lifestyle intervention will be effective for weight and glycated hemoglobin management to reverse or slow down the disease process among T2DM patients with overweight/obesity; 2) whether the intervention will be beneficial for improving biochemical indicators, body composition indicators, and exercise capacity among T2DM patients with overweight/obesity.

• Study Type: Interventional
• Enrollment (Actual): 120
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Shifeng Jin; Phone Number: 15098736866; Email: 2111210095@bjmu.edu.cn
• Study Contact Backup: Name: Li Li; Phone Number: 8613757426626; Email: lilyningbo@163.com

Study Locations

• China
  • Zhejiang
    • Ningbo, Zhejiang, China
      • Ningbo First Hospital
      • Contact: Shifeng Jin
      • Principal Investigator: Li Li, Bachelor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Meet the WHO diagnostic criteria for type 2 diabetes;
2. The duration of diabetes is less than 5 years;
3. HbA1c was between 6.5-11% in recent 3 months;
4. 18-65 years old;
5. 24kg/m2≤BMI#40kg/m2;
6. Weight loss within the past 3 months did not exceed 5% of initial weight;
7. Currently using a smartphone;
8. Voluntary participation.

Exclusion Criteria:

1. Pregnant or lactating woman, or planning a pregnancy within 6 months after recruitment;
2. Uncontrolled hypertension (resting blood pressure ≥ 160/100mmHg);
3. Treatment with insulin;
4. Acute complications of diabetes (diabetic ketoacidosis, hyperosmolar state, infection. etc) have occurred within the past 3 months, or one or more severe chronic complications of diabetes have existed, such as severe cardiovascular or cerebrovascular pathology (angina pectoris, myocardial infarction, grade III-IV heart failure, severe arrhythmia, transient cerebral ischemic attack, stroke, etc.), massive proteinuria (urinary albumin/creatinine ratio ≥300 mg/g), and severe diabetic foot, severe neuropathy, blurred vision.
5. Currently using weight-reducing products such as orlistat, or other medications that can significantly affect weight such as diuretics and hormones;
6. Severe cardiovascular and cerebrovascular diseases, respiratory diseases, hepatic and renal insufficiency, malignant tumors and other chronic consumptive diseases, active infections, and surgical history involving important organs within 3 months;
7. Contraindications to physical activity;
8. The presence of mental or cognitive impairment;
9. Current participation in other clinical trial projects;
10. Having the same family member involved in the research.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: lifestyle intervention; Weight monitoring: Participants are required to record the weighting data in the WeChat official account at least once a week to lose 5% or more of their initial body weight in 3 months.; Goals record: At baseline, the participants need to complete a behavioral goals questionnaire. All these behaviors are then ranked for each participant based on an algorithm that determines the participants'self-reported necessity, self-efficacy, and estimated caloric deficit from performing that behavior. The top six goals are assigned to each participant with two for every 4-week cycle.; Exercise: The form is the combination of aerobic exercise (3d/w) and resistance exercise(2d/w). Each participant will be equipped with a Huami watch as a means of monitoring.; Health education: Participants are provided with T2DM-related knowledge. They can also contact the endocrinologist online and offline.	Behavioral: lifestyle intervention; During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of "Weight Loss and Glucose Control".They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data.
No Intervention: usual-care control; Participants assigned to the control group will receive routine medical care and diabetes education, and be treated with hypoglycemic drugs under the guidance of endocrinologists according to the patient's condition and clinical treatment standards throughout their participation in the trial. After finishing the study, they will be offered healthy management as the participants in the multi-component lifestyle intervention group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Weight change from baseline	measured in kilograms (kg) and calculate the change percentage(%)	at end of the 3-month intervention
The change of HbA1c from baseline	measured in percent (%)	at end of the 3-month intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The change in body mass index (BMI) from baseline	Weight and height will be combined to report BMI in kg/m^2.	at end of the 3-month intervention
The change of waist circumference from baseline	measured in centimetre (cm)	at end of the 3-month intervention
The change of waist-to-hip circumference ratio from baseline	measure waist circumference and hip circumference to calculate waist-to-hip circumference ratio	at end of the 3-month intervention
The change of both systolic and diastolic blood pressures from baseline	measure systolic and diastolic blood pressure in millimeters of mercury (mmHg) by using electronic sphygmomanometer	at end of the 3-month intervention
The change of body fat percentage from baseline	measure body fat percentage (%) by bioelectrical impedance analysis	at end of the 3-month intervention
The change of blood lipids from baseline	measure total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in milligram/deciliter (mg/dL)	at end of the 3-month intervention
The change in muscle strength from baseline	measure grip strength in kilograms (kg) by hand dynamometer	at end of the 3-month intervention
The change in exercise capacity from baseline	The 3-Minute Step Test is an assessment for Cardiorespiratory Fitness. At the end of the 3 minutes, sit down and monitor the pulse for one full minute. Calculate step-test index with the recovery heart rate. The fitter you are, the quicker the heart rate will return to normal after exercise.	at end of the 3-month intervention
The change in life quality from baseline	It is measured in the form of the Short form health survey (SF-36), scored from 0 to 100, with higher scores associated with better quality of life.	at end of the 3-month intervention
The change in sleep quality from baseline	It is measured in the form of the Pittsburgh Sleep Quality Index (PSQI), scored from 0 to 21, with higher scores associated with worse quality of sleep.	at end of the 3-month intervention
The change in depression severity from baseline	It is measured in the form of the Pittsburgh Sleep Quality Index (PSQI), scored from 0 to 27, with higher scores associated with greater degree of depression.	at end of the 3-month intervention

Collaborators and Investigators

• Sponsor: Ningbo No. 1 Hospital
• Collaborators: Peking University
• Investigators: Principal Investigator: Li Li, Bachelor, Ningbo No. 1 Hospital

Study record dates

Study Major Dates

• Study Start (Actual): October 7, 2022
• Primary Completion (Actual): June 1, 2023
• Study Completion (Actual): July 1, 2023

Study Registration Dates

• First Submitted: September 22, 2022
• First Submitted That Met QC Criteria: September 27, 2022
• First Posted (Actual): September 30, 2022

Study Record Updates

• Last Update Posted (Actual): November 18, 2023
• Last Update Submitted That Met QC Criteria: November 15, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Overnutrition; Nutrition Disorders; Body Weight; Diabetes Mellitus, Type 2; Overweight
• Other Study ID Numbers: NBFH20220755

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No